9 Meters Biopharma Learn more Focused on rare and unmet needs in Gastroenterology

About 9 Meters Biopharma Inc.

9 Meters Biopharma, Inc. (Nasdaq: NMTR) is a rare and unmet needs focused GI company. The Company is advancing drug candidates for short bowel syndrome and celiac disease. 9 Meters is led by a strong management team with a history of bringing novel therapeutics to market, and the Company owns all global rights to their products, which are backed by more than 150 patents worldwide.

Pipeline

9 Meters is currently developing:

Vurolenatide: a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS)

Larazotide: a tight junction modulator, for the treatment of celiac disease in adults, with Fast Track designation from the FDA

NM-003: a long-acting GLP-2 agonist, being developed for an undisclosed rare GI indication

NM-102: a small molecule, being developed for an undisclosed rare GI indication